Krystal Biotech, Inc. Common Stock (KRYS) Financials
Key financial figures for Krystal Biotech, Inc. Common Stock (Q2 2026).
- Revenue
- $119M
- Net Income
- $55M
- EPS
- $1.85
- Total Assets
- $1.5B
- Operating Cash Flow
- $75M
Full income statement, balance sheet, and cash flow for Krystal Biotech, Inc. Common Stock on SentiSense.